1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > World Generic Markets 08 DECEMBER 2014

World Generic Markets 08 DECEMBER 2014

  • December 2014
  • -
  • Espicom Business Intelligence
  • -
  • 20 pages

Industry Trend Analysis - As Hatch-Waxman Turns 30, Actavis Demonstrates Matured Generic Industry
Industry Brief - MPP/AbbVie Sign Deal For HIV Paediatric Formulations Of Lopinavir/Ritonavir
Industry Trend Analysis - Focus On Generic Pricing Highlights Market Limitations
Industry Brief - IntelGenx Settles US Bupropion Litigation With Wockhardt
Industry Brief - Breckenridge Enters Generic Product Agreement With Pharmaceutics International
Industry Brief - Mylan Signs TAF Licensing Deal With Gilead
Industry Brief - Teva Launches Generic Exforge HCT Tablets In US
Industry Brief - Actavis Launches Guanfacine In US
Industry Brief - Perrigo Launches Diclofenac
Industry Brief - Dymista Litigation Against Apotex Initiated In US
Industry Brief - AstraZeneca And Ranbaxy Prevail In Esomeprazole Antitrust Litigation
Industry Brief - Daptomycin Litigation Produces Mixed Results For Cubist
Industry Brief - Natrol Completes Sale To Aurobindo
Industry Brief - ASBM Biosimilars Survey Reveals Education Need
Industry Brief - Consilient Health Launches Aripiprazole In UK
Industry Brief - Ranbaxy Launches EPIRUS’ biosimilar infliximab in India
Industry Brief - Zydus Launches Biosimilar Adalimumab In India
Industry Trend Analysis - Sun's Acquisition Of Ranbaxy Imminent

Table Of Contents

World Generic Markets 08 DECEMBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, ...

Biosimilar - Global Market Outlook (2016-2022)

Biosimilar - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • September 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs ...

Insulin Biosimilars - Global Market Outlook (2016-2022)

Insulin Biosimilars - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Insulin Biosimilars market is accounted for $xx million in 2015 and is expected to reach $xx million by 2022 growing at a CAGR of xx% from 2015 to 2022. Growing ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.